International Journal of Health Sciences and Research
[Indexed, Peer-Reviewed Journal]
Volume 16; Issue: 4; April 2026
Website: www.ijhsr.org
Review Article *ISSN: 2249-9571*

Biofilm-Mediated Antimicrobial Resistance in *Pseudomonas aeruginosa* and Emerging Therapeutic Strategies

Jha Kumari Anamika[1], Kadam Sharda[2]

[1]Associate Professor, Department of Microbiology, Ayaan Institute of Medical Sciences, Moinabad, Telangana
[2]Assistant Professor, Department of Microbiology, MGM Medical College, Vashi, Navi Mumbai

Corresponding Author: Dr. Kumari Anamika Jha

DOI: https://doi.org/10.52403/ijhsr.20260426

ABSTRACT

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that poses a serious challenge in clinical settings due to its intrinsic resistance and capacity to acquire additional resistance mechanisms. A key factor contributing to its persistence is its ability to form biofilms - complex, surface-attached microbial communities embedded in an extracellular polymeric substance (EPS). Within biofilms, bacterial cells exhibit altered phenotypes, reduced metabolic activity, and increased tolerance to antimicrobial agents and host immune responses. This review provides a comprehensive and updated synthesis of the molecular basis of biofilm formation, mechanisms underlying biofilm-associated antimicrobial resistance, host–pathogen interactions, clinical implications, diagnostic challenges, and evolving therapeutic strategies. Advances in quorum sensing inhibition, bacteriophage therapy, nanotechnology, and CRISPR-based approaches offer promising avenues for combating biofilm-associated infections. A multidisciplinary approach integrating molecular diagnostics, targeted therapies, and infection control measures is essential to mitigate the growing burden of *P. aeruginosa* biofilm-related infections.

Keywords: *Pseudomonas aeruginosa*, biofilm, antimicrobial resistance, quorum sensing, multidrug resistance, persister cells

INTRODUCTION

Antimicrobial resistance (AMR) has become a critical global health challenge, severely compromising the efficacy of currently available therapeutic interventions. A major contributor to this issue is the presence of biofilm-forming microorganisms, which are responsible for a large proportion of chronic infections and infections associated with medical devices (1,2). Among these, *Pseudomonas aeruginosa* is particularly significant due to its remarkable adaptability, ability to thrive in diverse environments, and possession of multiple resistance mechanisms (3).

In contrast to free-floating (planktonic) bacteria, biofilm-associated cells exist within highly organized microbial communities encased in a self-produced extracellular matrix composed of polysaccharides, proteins, and extracellular DNA. This matrix not only provides structural integrity but also serves as a protective barrier against antimicrobial agents (2,4). Additionally, bacteria within biofilms exhibit altered gene expression

patterns and metabolic states, which further enhance their ability to survive under hostile environmental conditions (5).

Clinically, *P. aeruginosa* is associated with a broad spectrum of infections, including ventilator-associated pneumonia, urinary tract infections, burn wound infections, and chronic pulmonary infections in patients with cystic fibrosis (3,6). The chronic and recurrent nature of these infections is largely attributed to biofilm formation, which significantly reduces the effectiveness of standard antibiotic therapies

Biofilm Formation: Stages and Regulatory Mechanisms

Initial Attachment

Biofilm development begins with a reversible adhesion of bacterial cells to surfaces, mediated by structures such as flagella, pili, and various surface adhesins. This initial interaction is influenced by environmental factors including pH, temperature, and nutrient availability (4,5).

Irreversible Attachment and Microcolony Formation

Following initial adhesion, bacteria produce extracellular polymeric substances (EPS) that facilitate firm attachment to the surface. This leads to the formation of microcolonies as bacterial cells proliferate and aggregate (5).

Maturation

As the biofilm matures, it develops into a complex three-dimensional structure containing water channels that enable the transport of nutrients and removal of waste products. This stage is regulated by intracellular signaling molecules, particularly cyclic di-GMP (6).

Dispersion

In the final stage, bacterial cells detach from the mature biofilm and disperse to colonize new environments, thereby contributing to the dissemination of infection (4).

Mechanisms of Biofilm-Associated Antimicrobial Resistance

Biofilms exhibit a high level of antimicrobial resistance due to an interplay of structural, physiological, and molecular factors. The EPS matrix functions as a diffusion barrier, restricting the penetration of antimicrobial agents into the deeper layers of the biofilm (2,4).

Moreover, biofilms display pronounced metabolic heterogeneity, wherein cells in the outer regions are metabolically active, while those in the inner regions exist in a slow-growing or dormant state. This heterogeneity diminishes the effectiveness of antibiotics that primarily target actively dividing cells (3,5).

In addition, biofilm-associated bacteria activate multiple stress-response mechanisms, including oxidative stress pathways and the SOS response system, which enhance bacterial survival under antimicrobial stress (1,2). Overexpression of efflux pumps and adaptive changes in gene regulation further decrease intracellular antibiotic concentrations, contributing to increased resistance (3).

Collectively, these mechanisms establish a highly protective microenvironment that significantly reduces antibiotic efficacy and facilitates the persistence and recurrence of infections (6).

Quorum sensing (QS) is a population density–dependent communication mechanism that allows bacteria to synchronize gene expression collectively. In *Pseudomonas aeruginosa*, multiple QS systems, including Las, Rhl, and PQS, play a crucial role in regulating biofilm formation, production of virulence factors, and the development of antimicrobial resistance (7,8).

These regulatory systems function through the production and accumulation of signaling molecules, particularly acyl-homoserine lactones (AHLs), which increase in concentration as bacterial population density rises. Once a critical threshold is reached, these molecules interact with transcriptional regulators,

leading to coordinated changes in gene expression (9). In addition to initiating biofilm formation, QS also contributes to the maturation and architectural organization of biofilms, making it an attractive target for novel therapeutic interventions (7).

Despite the frequent use of combination antibiotic therapies, their clinical success is often limited due to the presence of persister cells—phenotypically dormant bacterial variants capable of surviving antibiotic exposure without acquiring genetic resistance (9,10). These cells exhibit minimal metabolic activity, which significantly reduces the efficacy of antibiotics that target actively dividing bacteria. Consequently, persister cells play a major role in treatment failure, chronic infection, and recurrence following antimicrobial therapy.

Moreover, the proportion of persister cells is significantly higher within biofilms compared to planktonic bacterial populations, further contributing to the inherent tolerance observed in biofilm-associated infections (9). This highlights a major limitation of conventional antimicrobial approaches, which are primarily designed to eliminate actively growing bacteria rather than dormant subpopulations. As a result, complete eradication of biofilm-associated infections remains a considerable clinical challenge.

Additionally, the biofilm microenvironment provides further protection to persister cells by restricting antibiotic penetration and promoting the activation of stress-response pathways, thereby enhancing bacterial survival under adverse conditions (11).

Diagnostic Challenges and Advances

Traditional culture methods often fail to detect biofilm-associated bacteria due to their altered growth characteristics. Advanced diagnostic techniques such as PCR, next-generation sequencing, and imaging methods provide improved detection and characterization (10,12).

Emerging biomarkers may help distinguish between colonization and active infection, facilitating more accurate diagnosis and treatment decisions (12).

Current Treatment Strategies

Managing biofilm-associated *Pseudomonas aeruginosa* infections continues to be a major clinical challenge, primarily due to the organism's inherent resistance mechanisms and the protective nature of the biofilm matrix. Although antibiotic therapy remains the cornerstone of treatment, its clinical efficacy is often limited, thereby highlighting the need for more advanced and combination-based therapeutic approaches.

Antibiotic Therapy and Combination Regimens

Conventional treatment typically involves antipseudomonal antibiotics such as β-lactams, aminoglycosides, and fluoroquinolones. Combination regimens are commonly utilized to improve antimicrobial effectiveness and reduce the likelihood of resistance development (13). However, the restricted penetration of antibiotics and the altered physiological state of bacteria within biofilms frequently result in suboptimal therapeutic outcomes.

Adjunctive Anti-Biofilm Strategies

To enhance treatment efficacy, adjunctive approaches targeting the biofilm matrix are being explored. Enzymatic agents, including DNase and dispersin B, can degrade extracellular polymeric substances (EPS), thereby facilitate improved antibiotic diffusion and increase bacterial susceptibility (14). Disrupting the structural integrity of biofilms is therefore considered a critical component of effective therapy.

Quorum Sensing Inhibition

Interfering with quorum sensing pathways offers a promising strategy to disrupt bacterial communication, thereby reducing virulence factor expression and inhibiting biofilm development. Quorum sensing

inhibitors have the advantage of attenuating pathogenicity without imposing strong selective pressure for resistance (15).

Bacteriophage Therapy

Bacteriophage-based therapy has re-emerged as a potential alternative or adjunct to conventional antibiotics, especially in cases involving multidrug-resistant *P. aeruginosa*. Phages can infiltrate biofilms, lyse bacterial cells, and, in some cases, produce enzymes capable of degrading the biofilm matrix (16).

Antimicrobial Peptides (AMPs)

Antimicrobial peptides are gaining attention as novel therapeutic agents due to their broad-spectrum antimicrobial activity and rapid bactericidal action. These peptides primarily target bacterial membranes and have shown effectiveness against biofilm-associated pathogens (17).

Nanotechnology-Based Drug Delivery Systems

Nanotechnology-based approaches provide innovative solutions for overcoming biofilm-associated resistance. Nanoparticles can enhance targeted drug delivery, improve penetration into biofilms, and allow sustained release of antimicrobial agents at infection sites, thereby increasing therapeutic effectiveness (18).

Device Management and Infection Control

In clinical practice, the removal or replacement of contaminated medical devices is often essential for the successful management of biofilm-associated infections. Additionally, strict infection control measures, including proper sterilization techniques and antimicrobial stewardship programs, are crucial in preventing biofilm formation and reducing the incidence of infections (19).

Prevention and Infection Control

Prevention of biofilm-associated *Pseudomonas aeruginosa* infections is essential in clinical settings, especially among patients with invasive devices. Effective control requires an integrated approach combining infection control practices, antimicrobial stewardship, and environmental hygiene.

Strict adherence to standard precautions, including hand hygiene, use of personal protective equipment, and aseptic techniques, plays a key role in minimizing transmission in healthcare environments. Continuous surveillance of healthcare-associated infections is also important for early detection and outbreak control (20).

Medical devices such as catheters and ventilators are common sites for biofilm formation; therefore, proper insertion, maintenance, and timely removal are critical. The use of antimicrobial-coated devices can further help prevent bacterial adherence (21).

Environmental sources, particularly moist hospital areas, can act as reservoirs for *P. aeruginosa*. Regular cleaning and disinfection using appropriate agents are necessary to reduce contamination and prevent cross-infection (22).

Appropriate antibiotic use through antimicrobial stewardship programs is crucial to limit resistance development by optimizing drug selection, dosage, and treatment duration (23).

Although vaccines are not yet widely available, ongoing research into immunological and host-directed therapies shows promise in enhancing resistance to infection (24). Additionally, emerging strategies such as quorum sensing inhibitors and biofilm-disrupting agents may help prevent early bacterial colonization and biofilm formation (25).

CONCLUSION

Biofilm-associated antimicrobial resistance in *Pseudomonas aeruginosa* represents a significant and persistent challenge in modern clinical practice, driven by the complex interplay of structural barriers, metabolic heterogeneity, and adaptive stress-response mechanisms. The ability of

this organism to form highly organized biofilms not only enhances its survival in hostile environments but also markedly reduces the efficacy of conventional antimicrobial therapies (1,2).

A critical factor contributing to therapeutic failure is the presence of persister cells and biofilm-specific tolerance mechanisms, which enable bacterial populations to withstand prolonged antibiotic exposure without acquiring stable genetic resistance (9,10). These characteristics, combined with limited drug penetration and altered physiological states within the biofilm, contribute to chronic and recurrent infections that are difficult to eradicate.

Clinically, biofilm-associated infections are linked to severe outcomes, particularly in vulnerable patient populations, and are commonly observed in conditions such as ventilator-associated pneumonia, chronic lung infections, and device-related infections (12). The increasing prevalence of multidrug-resistant *P. aeruginosa* further complicates treatment and underscores the urgent need for improved therapeutic strategies.

Recent advances in microbiology have introduced promising approaches, including quorum sensing inhibitors, bacteriophage therapy, nanotechnology-based drug delivery systems, and CRISPR-Cas–mediated gene targeting, all of which offer potential avenues for overcoming biofilm-associated resistance. Additionally, the integration of artificial intelligence and molecular diagnostics into clinical practice may enhance early detection and guide targeted therapy, improving patient outcomes.

In conclusion, a deeper understanding of biofilm biology, coupled with continued research into novel therapeutic strategies, is essential to combat the growing threat of biofilm-associated infections. Coordinated efforts at the clinical, research, and public health levels will be crucial in reducing the burden of antimicrobial resistance and improving the management of *Pseudomonas aeruginosa* infections.

Declaration by Authors

Ethical Approval: Not applicable

Acknowledgement: None

Source of Funding: None

Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. Fernández-Billón M, Llambías-Cabot AE, Jordana-Lluch E, Oliver A, Macià MD. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa* biofilms. Biofilm. 2023 May 2; 5:100129. doi: 10.1016/j.bioflm.2023.100129.
2. Liu HY, Prentice EL, Webber MA. Mechanisms of antimicrobial resistance in biofilms. NPJ Antimicrob Resist. 2024;2(1):27. doi: 10.1038/s44259-024-00046-3.
3. Zhao Y, Xu H, Wang H, Wang P, Chen S. Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances. Mol Biomed. 2024 Nov 27;5(1):62. doi: 10.1186/s43556-024-00221-y.
4. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010 Sep;8(9):623-33. doi: 10.1038/nrmicro2415.
5. Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017 May 1;41(3):276-301. doi: 10.1093/femsre/fux010.
6. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.
7. Sanya, D.R.A., Onésime, D., Vizzarro, G. *et al.* Recent advances in therapeutic targets identification and development of treatment strategies towards *Pseudomonas aeruginosa* infections. *BMC Microbiol* 23, 86 (2023). https://doi.org/10.1186/s12866-023-02832-x
8. Meletis G, Karastergiou E. Resistance mechanisms and therapeutic strategies for *Pseudomonas aeruginosa* infections. Ther Adv Infect Dis. 2025 Oct 29; 12:20499361251388382. doi: 10.1177/20499361251388382.
9. Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J

Bacteriol. 2010 Dec;192(23):6191-9. doi: 10.1128/JB.01651-09.
10. Lewis, K. Persister cells, dormancy and infectious disease. *Nat Rev Microbiol* 5, 48–56 (2007). https://doi.org/10.1038/nrmicro1557
11. Andre C. Kalil, Mark L. Metersky, Michael Klompas, John Muscedere, Daniel A. Sweeney, Lucy B. Palmer, Lena M. Napolitano, Naomi P. O'Grady, John G. Bartlett, Jordi Carratalà, Ali A. El Solh, Santiago Ewig, Paul D. Fey, Thomas M. File, Marcos I. Restrepo, Jason A. Roberts, Grant W. Waterer, Peggy Cruse, Shandra L. Knight, Jan L. Brozek, Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society, *Clinical Infectious Diseases*, Volume 63, Issue 5, 1 September 2016, Pages e61–e111, https://doi.org/10.1093/cid/ciw353
12. Sinha M, Jupe J, Mack H, Coleman TP, Lawrence SM, Fraley SI. Emerging Technologies for Molecular Diagnosis of Sepsis. Clin Microbiol Rev. 2018 Feb 28;31(2):e00089-17. doi: 10.1128/CMR.00089-17.
13. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024 Aug 7:ciae403. doi: 10.1093/cid/ciae403.
14. Kaplan JB. Therapeutic potential of biofilm-dispersing enzymes. Int J Artif Organs. 2009 Sep;32(9):545-54. doi: 10.1177/039139880903200903.
15. LaSarre B, Federle MJ. Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol Biol Rev. 2013 Mar;77(1): 73-111. doi: 10.1128/MMBR.00046-12.
16. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013 Jun;8(6):769-83. doi: 10.2217/fmb.13.47.
17. Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020 May;19(5):311-332. doi: 10.1038/s41573-019-0058-8.
18. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15. doi: 10.1016/j.addr.2013.07.011.
19. Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015 May;21 Suppl 1:S1-25. doi: 10.1016/j.cmi.2014.10.024.
20. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009 Dec;73(4): 305-15. doi: 10.1016/j.jhin.2009.04.019.
21. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006 Sep;81(9):1159-71. doi: 10.4065/81.9.1159.
22. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in healthcare-associated infections. Curr Opin Infect Dis. 2013 Aug;26(4):338-44. doi: 10.1097/QCO.0b013e3283630f04.
23. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793–8. https://doi.org/10.1016/j.cmi.2017.08.026
24. P Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014 Apr;13(4):507-19. doi: 10.1586/14760584.2014.890053.
25. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013 May;(136):1-51. doi: 10.1111/apm.12099.

How to cite this article: Jha Kumari Anamika, Kadam Sharda. Biofilm-mediated antimicrobial resistance in *Pseudomonas aeruginosa* and emerging therapeutic strategies. *Int J Health Sci Res.* 2026; 16(4):219-224. DOI: *https://doi.org/10.52403/ijhsr.20260426*

******